Login to Your Account

Earnings Roundup

Biogen Idec Grows Revenue 7% in 'High Quality' 1Q Miss

By Marie Powers
Staff Writer

Wednesday, May 2, 2012
Biogen Idec Inc. added 1,900 Tysabri (natalizumab) patients during the first three months of 2012, increasing revenues from the multiple sclerosis drug by 14 percent year over year to $286 million, on global in-market sales of $399 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription